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Objective: Systemic Sclerosis is an autoimmune connective tissue disease which
results in fibrosis of the skin and lungs. The disease is characterized by activation of
myofibroblasts but what governs this is unknown. Gremlin-1 is a BMP antagonist that is
developmentally regulated and we sought to investigate its role in Systemic Sclerosis.
Methods: Dermal fibroblasts were transfected with Grem1pcDNA3.1 expression
vectors or empty vectors. Various markers of myofibroblasts were measured at the
mRNA and protein levels. Scratch wound assays were also performed. Media Transfer
experiments were performed to evaluate cytokine like effects. Various inhibitors of TGF-β
signaling and MAPK signaling were used post-transfection. siRNA to Gremlin-1 in SSc
dermal fibroblasts were performed to evaluate the role of Gremlin-1. Different cytokines
were incubated with fibroblasts and Gremlin-1 measured. Bleomycin was used as model
of fibrosis and immunohistochemistry performed.
Results: Overexpression of Gremlin-1 was achieved in primary dermal fibroblasts
and lead to activation of quiescent cells to myofibroblasts indicated by collagen
and α-Smooth muscle actin. Overexpression also led to functional effects. This
was associated with increased TGF-β1 levels and SBE luciferase activity but not
increased Thrombospondin-1 expression. Inhibition of Gremlin-1 overexpression cells
with antibodies to TGF-β1 but not isotype controls led to reduced collagen and various
TGF-β pathway chemical inhibitors also led to reduced collagen levels. In SSc cells
siRNA mediated reduction of Gremlin-1 reduced collagen expression and CTGF gene
and protein levels in these cells. IL-13 did not lead to elevated Gremlin-1 expression
nor did IL-11. Gremlin-1 was elevated in an animal model of fibrosis compared to
NaCl-treated mice.
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Conclusion: Gremlin-1 is a key regulator of myofibroblast transition leading to
enhanced ECM deposition. Strategies that block Gremlin-1 maybe a possible
therapeutic target in fibrotic diseases such as SSc.
Keywords: fibrosis, ECM, BMP, gremlin-1, collagen
INTRODUCTION
Gremlin-1 is a highly conserved known bone morphogenetic
protein (BMP) antagonist which is critical in embryogenesis
(Brazil et al., 2015). It is a member of the Transforming
Growth Factor-β superfamily and includes Gremlin-1 and
noggin (Stafford et al., 2011; Brazil et al., 2015). BMPs are
glycosylated ligands that induce bone formation and as well
as that can regulate development of adipose, neurological,
ophthalmic, cardiovascular, and musculoskeletal systems and
as such are morphogens (Schmidt et al., 1995; Nickel and
Mueller, 2019). BMPs usually function by short range diffusion
and bind serine/threonine kinase receptors (type I and type II
receptors), which triggers phosphorylation of receptor induced
Smads (Nickel and Mueller, 2019). The main Smads activated
downstream of BMP receptors are R-Smad 1/5/9. BMP signaling
is tightly regulated by multiple extracellular binding proteins
which regulate BMP diffusion and thus control BMP signaling
spatially and temporally. Gremlin-1 is the major BMP antagonist
that maintains proper limb development during embryogenesis
and aberrant expression in adults is associated with orofacial cleft
(Mangold et al., 2010) and various cancers (Jang et al., 2017;
Lieberman et al., 2017).
Systemic Sclerosis (SSc) is an idiopathic autoimmune
disease characterized by inflammation, vascular abnormalities
and fibrosis (Denton and Khanna, 2017; Hinchcliff and
O’Reilly, 2020). The etiology of the disease remains unknown
and few treatments are available. The disease is mainly
associated with skin and lung fibrosis with increased
extracellular matrix, in particular, collagen, underlying
the pathology of the disease (Henderson et al., 2019b).
Activated myofibroblasts are key cell types mediating the
deposition of ECM leading to fibrosis but what precisely
governs their activation remains elusive (Kisseleva and
Brenner, 2008; Volkmann and Varga, 2019). Given that
development pathways reactivation is associated with cancer
it could be proposed that such pathways are operative in SSc
(Bertrand et al., 2012).
Indeed, one of the hallmarks of cancer is reactivation of the
pathways that control cellular differentiation during development
and in relation to SSc, aberrant activation of Wnt pathways
drive fibrosis. Increased levels of the BMP antagonist Gremlin-
1 are associated with fibrosis of the kidney (Dolan et al.,
2005; Li et al., 2012),liver (Yang et al., 2012), lung (Koli et al.,
2006), and ocular system (Lee et al., 2007). We have also
previously identified Gremlin-1 as mediating fibrosis in dermal
fibroblasts after Interleukin-6 stimulation and elevated levels
have been demonstrated in PCR arrays from SSc tissue biopsies
(Meyringer et al., 2007). This study aims to evaluate the role




Dermal fibroblasts were obtained from 4 healthy control derived
from skin tissue from female healthy donors undergoing
surgery for adipose tissue removal. Cells were maintained in
DMEM with the addition of 10% (v/v) heat inactivated fetal
calf serum (Gibco), 100 units/ml penicillin (Life technologies,
United Kingdom) and 100 µg/ml streptomycin in 5% CO2 at
37◦C in an incubator until required for experimental protocols.
SSc dermal fibroblasts were taken from 3 patients that have been
clinically diagnosed with early diffuse SSc by a clinical consultant
rheumatologist. Early being defined as <2 years from the first
non-Raynaud’s symptom. All three patients were female and were
treatment naïve. Local research ethics was obtained for this from
the NHS NRES committee, Hamsted, London reference 6398.
Lesional skin biopsies were taken by punch biopsy and cultured
in standard media described above until the fibroblasts had
outgrown and then the cells were removed pelleted and washed
three times and replated into standard tissue culture plates.
pcDNA3.1a Plasmid Generation and
Transfection
A DNA fragment containing the entire coding sequence
for Gremlin-1 was amplified by RT-PCR on cDNA from
HK-2 cells using forward primer 5′- GACAGTGAATTCA
TGAGCCGCACAGCCTACACG-3′ and reverse primer 3′-
GGATTTTCTAGAATCCAAATCGATGGATATGCA-5′ and
RedTaq R© DNA polymerase at an annealing temperature of
55◦C and was ligated into pcDNA3.1/myc-his (Invitrogen) and
transformed into competent cells as described (Church et al.,
2015). Positive colonies from LB plates were picked and grown in
LB supplemented with selection antibiotic and plasmids isolated
using maxiprep kits (Qiagen, United Kingdom).
Actively dividing dermal fibroblasts were trypinised and
75,000 cells seeded into an Eppendorff and pelleted. The
cell pellet was then resuspended in Ingenio R© solution
(Mirus bio, Wisconsin, United States) and transferred
to a 4 mm electroporation cuvette (Cell Projects Ltd.,
Kent, United Kingdom) with 10 µg of corresponding
pDNA or pDNA combined with 80 nM siRNA,
Scramble—5′AATTCTCCGAACGTGTCACGT3′ Gremlin-
1–5′CTGCCGGCTGCTGAAGGGAAA3′. A single electrical
pulse of 960 µF, 250 V and Ohms was delivered using a Bio-Rad
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Gene Pulser. Cell debris removed after 4 h and viable cells
incubated for the appropriate time course.
Western Blotting
Cell lysates were obtained using RIPA buffer and the protein
quantified using a BCA assay (Thermo Fisher Scientific,
Massachusetts, United States) 10 µg of total protein was ran on
a denaturing SDS-PAGE and transferred via wet transfer to 0.45
µM Nitrocellulose paper. The blot was then blocked using 5%
milk PBST and incubated overnight at 4◦C in either Collagen
1 1:500, (Abcam, ab138492), Myc 1:1,000, (Cell Signaling
technologies, Danvers, United States #2276), alpha SMA 1:1,000,
(Abcam, ab7817), and Alpha tubulin 1:2,000, (Abcam, ab7291)
used a loading control. The membrane was then washed, and
secondary antibody conjugated to Horseradish peroxidase (HRP)
(Sigma Aldrich, United Kingdom) applied at room temperature
for 1 h. Blots were visualized using ECL Prime (GE Healthcare,
Illinois, United States) and G:box (Syngene, United States).
IL-6 and IL-11 Stimulation Experiments
Dermal fibroblast was seeded into 6 well tissue culture plates to
adhere they were then washed twice with PBS and stimulated
with 20 ng/ml recombinant IL-6 and 25 ng/ml recombinant
soluble IL-6 receptor (R&D systems, United Kingdom). They
were then incubated for 48 h in culture after which the cells were
lysed and qRT-PCR was performed for Gremlin-1 as described.
In some experiments the IL-6 and soluble IL-6 stimulation
was pretreated for 1 h with the STAT3 inhibitor S31-201
(Sigma Aldrich, United Kingdom) 15 µM in DMSO, which
was previously demonstrated to be antifibrotic in SSc dermal
fibroblasts (Chakraborty et al., 2017). After the appropriate time
the cells were lysed and Gremlin-1 quantified by qRT-PCR.
In some experiments the IL-6 was replaced with human
recombinant IL-11 (R&D systems, United Kingdom) at 10 ng/ml.
This dose was chosen based on dose response performed in our
recent publication in which we performed dose response curves
(Adami et al., 2021).
IL-13 Stimulation Experiments
Healthy dermal fibroblasts were culture in standard six well
plates until confluent. Media was removed and replaced with
media containing recombinant IL-13 100 ng/ml (R&D Systems,
United Kingdom) at which we have previously demonstrated to
give a robust increase in collagen at both mRNA and protein
levels in fibroblasts (O’Reilly et al., 2016). After 24 and 48 h
cells were lysed and Gremlin-1 quantified by qRT-PCR. At 24 h
Col1A1 was also quantified by qRT-PCR.
Quantitative RT-PCR
RNA extraction was performed as per the Qiagen RNeasy
kit (Qiagen, Hilden Germany) and 1 µg converted to cDNA
using Nanoscript 2 reverse transcriptase (Primer Design Ltd.,
Southampton, United Kingdom). A master made up of 100 nM
of forward and reverse primers (Table 1), precisionFAST
qPCR Master Mix (Primer Design Ltd., Southampton,
United Kingdom) and 5 µl cDNA. Relative levels were
normalized to 18s and compared using the 11Ct method to
obtain fold change relative to control as previously described
(Henderson et al., 2019a).
Media Transfer
Post-transfection cells were incubated for 48 h. After this
time conditioned media was then removed and placed on to
un-transfected healthy dermal fibroblasts different from those
transfected. This media was then left for a further period of time
of 48 h after which cells were lysed and subjected to Western
blotting with specific antibodies.
Scratch Assay
Post electroporation confluent healthy dermal fibroblasts were in
24 well plates at 100,000 cells/well, then left to adhere in standard
DMEM media as described. After 24 h they were scratched
with a p5 sterile pipette tip and images taken using a Leica
DMi1 microscope every 8 h, analysis of this images conducted
via Image J software and% wound closure obtained by deriving
from the wound area.
Small Interfering RNA Transfection of
Gremlin-1
SSc dermal fibroblasts from 3 independent early (<2 years
from non-Raynauds symptom) diffuse SSc donors were seeded
into 24 well plates and transfected with siRNA (80 nM)
scramble or Gremlin-1 specific siRNA using DharrmaFECT1©
transfection reagent (Thermo, United Kingdom) according to the
manufacturers instructions. Forty-eight hours post-transfection
of either scramble or Gremlin-1 siRNA cells were lysed and RNA
harvested to confirm Gremlin-1 knockdown at the mRNA levels
using qPCR. Data was normalized to the housekeeping gene 18S.
In some experiments cells were lysed and subjected to Western
blotting for CTGF protein expression 1:300, (Ab6992) (Abcam,
United Kingdom).
Enzyme Linked Immunosorbent Assay
(ELISA)
After transfection media was collected and stored immediately
at −80◦C until used further. Media was measured for TGF-
β1 and Thrombospondin-1 (TSP-1) by standard specific
ELISA (R&D Systems, United Kingdom) following the
manufacturer’s instructions. All samples were run in triplicate
with internal controls.
SBE Luciferase Assay
Plasmids containing 4 repetitions of GTCTAGAC Smad3/4
binding motif element with luciferase was gifted by Prof. Jorg
Distler. This was transfected into healthy dermal fibroblasts
using lipofectamine 2000 (Invitrogen, United Kingdom) per
manufacturer’s instructions at 1.1 µg and 6 h post transfection
cells were washed twice in warm PBS and media was added from
empty plasmid or Gremlin-1 transfected fibroblasts and then
left for 6 h after which time luciferase was measured using a
luminometer. Data is expressed as percentage compared to empty
pcDNA3.1 vector media only set at 100%. In some experiments
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TABLE 1 | PCR primer sequences used in this study.
Gene Forward primer Reverse primer
GREM1 5′ TAT GAG CCG CAC AGC CTA CA-3′ 5′ GCA CCT TGG GAC CCT TTC TT 3′
COL1A1 5′ CAA GAG GAA GGC CAA GTC GAG G 3′ 5′ CGT TGT CGC AGA CGC AGA T 3′
CTGF 5′ AAT GCT GCG AGG AGT GGG T 3′ 5′CGG CTC TAA TCA TAG TTG GGT CT 3′
18s 5′ CGA ATG GCT CAT TAA ATC AGT TAT GG 3′ 5′ TAT TAG CTC TAG AAT TAC CAC AGT TAT CC 3′
recombinant TGF-β1 was added (10 ng/ml) (R&D systems,
United Kingdom) plus and minus neutralizing TGF-1 antibody
1 µg/ml (Mab1835 clone; R&D systems, United Kingdom) to
confirm specificity of the antibody in use.
Sircol Assay
After specific experimental conditions explained the media was
removed from the cells and analyzed by the Sircol Assay
(Biocolor, Newtontown abbey). Briefly media was removed and
centrifuged at 377 g for exactly 5 min. One milliliter of Sircol
dye was added to 200 µl of supernatant and incubated for
30 min after which the complex was centrifuged at 16,770 g
for 10 min to spin the formed collagen-dye complex. After
removal of the supernatant droplets were dissolved in 1 ml
Sircol alkali reagent and absorbance measured at 540 nm on a
spectrophotometer. A standard curve was constructed and data
was read of the standard curve.
TGF-β Inhibitor Treatment Experiments
Immediately post transfection with pcDNA3.1 or
pcDNA3.1Grem1, cells were treated with antibodies to TGF-β1
at 1 µg/ml (Mab1835 clone; R&D systems, United Kingdom)
or a matched isotype control antibody (1 µg/ml) in 24 well
plates to neutralize TGF-β1 levels in the media of the cells. After
48h the media was measured for collagen by Sicrol assay as
described above. As described above cells were transfected with
SBE luciferase plasmid plus and minus TGF-β1 and neutralizing
antibody. To inhibit the TGF-β receptor post transfection we
immediately treated the cells with LY2109761 (Sigma Aldrich,
United Kingdom) at 70 nM and post 48 h the media was collected
and collagen quantified. To determine the role of the TGF-β
non-canonical pathway we incubated the dermal fibroblasts with
U0126, an MEK inhibitor (Cell Signaling, United Kingdom) 10
µM in DMSO, transfection or not and after 48 h the cell media
was harvested and collagen measured by the Sircol assay.
MTT Assay
SSc dermal fibroblasts were cultured in 96 well plate and
transfected with either scramble siRNA or Gremlin-1
specific siRNA (80 nM) using DharmaFECT1© (Thermo,
United Kingdom) according to manufacturers instructions, 48 h
post transfection cells were subject to the MTT assay (Roche)
which is based on the cleavage of tetrazolium salt. The plate was
read in a plate reader at 570 nm. Data is presented at absorbance
at 570 nM from n = 3 SSc donors.
Gremlin-1 Immunohistochemistry
Mice were treated with either NaCl or injections of bleomycin
as described previously (Akhmetshina et al., 2012). Briefly
these are male C57BL6/6 mice (n = 4) were repeated injected
subcutaneously with 100 µL of 0.5 mg/ml bleomycin every
other day for 4 weeks. 0.5% NaCl injection serves as controls.
After sacrifice tissue was processed and sections cut. After
wax removal sections were blocked with 2% BSA for 1 h
antibody to Gremlin-1 was incubated overnight at 1:50 dilution
(AB4716, Abnova, Taiwan) or matched isotype control antibody
in immunohistochemistry buffer at 4◦C and then developed with
DAB substrate. Tissue was counterstained with haemotoxylin
before dehydration through ascending ethanols and coversliped.
Images were taken with a microscope at X20 magnification.
Tissue was also stained by Masson’s trichrome stain as
described previously (Chakraborty et al., 2017), this demonstrates
connective tissue. Images were taken with a light microscope at
X10 magnification.
Statistics
In many comparisons we used Student’s t-test and in multiple
comparisons we used Analysis of Variance (ANOVA) to compare




Due to previously demonstrating that Gremlin-1 recombinant
protein increased collagen we sought to define this using a
different model system in which endogenous Gremlin-1 is used.
We used a gremlin-1 overexpression plasmid with a myc-tag for
identification as Gremlin-1 antibodies, although commercially
available are not specific, with either no signal present or
bands at the incorrect molecular weight. Transfection of normal
human dermal fibroblasts with an over expressing Gremlin-
1 vector increased Collagen 1 protein compared with control
vector only particularly after 48 h post transfection (Figure 1A).
Gremlin-1 mRNA was also increased in the overexpressed
cells (Figure 1B).
xInterestingly, the myofibroblast marker alpha smooth muscle
actin (αSMA) was also increased in gremlin-1 overexpressing
cells (n = 3) (Figure 1C). The transfer of conditioned media
from transfected to un-transfected cells yielded similar results, in
terms of increased Collagen 1 to that of transfected cells (n = 3)
(Figures 2A,B). This result would connote gremlin-1 is acting
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 June 2021 | Volume 9 | Article 681061
fcell-09-681061 May 31, 2021 Time: 18:26 # 5
Duffy et al. Gremlin-1 Mediates Myofibroblast Differentiation
FIGURE 1 | Gremlin-1 increases myofibroblast differentiation. (A) Normal human dermal fibroblasts were transfected with pcDNA3.1a construct with or without the
human Gremlin-1 gene. Western blots were conducted at 12, 24, and 48 (n = 3) h to assess its affects on the key ECM molecule collagen 1 (n = 3). (B) qPCR was
performed at 48 h to assess the transcription of Gremlin-1. Data is normalized to 18s and shown as fold change compared to empty vector plasmid (n = 3).
(C) Gremlin-1 increases myofibroblast marker alpha smooth muscle actin. Normal human dermal fibroblasts were transfected with the plasmid construct pcDNA3.1a
with or without the insert for human Gremlin-1 as detailed in the methods. Forty-eight hours post-transfection cells were lysed and a western blot performed with
specific antibodies. Alpha Tubulin is the loading control (n = 3).
in cytokine-like manner or Gremlin-1 signaling is leading to an
increase in pro-fibrotic cytokine(s), such as TGF-β 1.
TGF-β1 Does Not Increase Gremlin-1
mRNA in Dermal Fibroblasts
Previous studies have shown a link between TGF-β1 signaling
and Gremlin-1 in both ocular and kidney tissue, with
neutralization of TGF-β2 reducing Gremlin-1 expression in
mesangial cells (McMahon et al., 2000). It is also clear that
in SSc, TGF-β1 is a clear and potent pro-fibrotic molecule
(Lafyatis, 2014; Györfi et al., 2018). We thus hypothesized
that stimulation with TGF-β1 would increase the transcription
of Gremlin-1 mRNA. Here we showed that treatment of
Normal Healthy Dermal Fibroblasts (NHDF) with 10 ng/mL
recombinant TGF-β1 had no significant effect on Gremlin-1
mRNA expression at both 24 and 48 h, fold change of 0.97 and
1.12, respectively (n = 5, Student’s t-test 24 h P = 0.37 and 48 h
P = 0.95).
Gremlin-1 Promotes Migration in Dermal
Fibroblasts
Standard wound healing scratch assays were conducted to
investigate the migratory effects of increased Gremlin-1 on the
NHDF. The activation of fibroblasts in vivo results in a changed
intermediary phenotype resulting in increased migration and
proliferation, before their eventual conversion to the prototypical
myofibroblast (Schmidt et al., 1995). Figure 3A demonstrates
representative image of wound healing after transfection and
scratching. Analysis of migration as a percentage of wound
closure via image J software revealed increased migration
in NHDF overexpressing Gremlin-1 as compared to vector
only expressing construct (Figure 3B). Percentage wound
closure from the initial wound was 50% in the pcDNA3.1a
construct and 68% in the construct containing the Gremlin-
1 insert (Figure 3B) (n = 3, t-test, P = 0.0012∗∗, Values are
mean± SEM).
Gremlin-1-Mediated Increase Collagen 1
Can Be Attenuated by siRNA Knockdown
Gremlin-1 transfected NHDF cells were co-transfected with
Gremlin-1 siRNA to determine if the effects on the ECM proteins
could be attenuated. As the results in Figure 4A show when
co-transfected with siRNA Collagen 1 does not increase upon
overexpression of Gremlin-1 (Figure 4B). Collagen secretion
was also significantly reduced by siRNA to Gremlin-1 also
(Figure 4C) (P = 0.0095 ANOVA).
This data combined with the data collected from the media
transfer assays further suggestive of a rapidly acting cytokine
like role for Gremlin-1. Previous data shows Gremlin-1 mRNA
is unchanged by rTGF-β1 treatment, we further investigated if
the secretion of TGF-β1 was affected by the over expression of
Gremlin-1 protein.
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FIGURE 2 | Gremlin-1 overexpression conditioned medium increased collagen expression. (A) Normal human dermal fibroblasts were transfected with plasmid
pCDNA3.1a with or without the insert for human Gremlin-1, after 48 h the media was removed and then placed onto new dermal fibroblasts after a further 48 h cells
were lysed and subjected to western blotting for the specified proteins. (B) Densitometric analysis of collagen after plasmid transfection data is normalized to alpha
tubulin expression and shown as fold change compared to pcDNA3.1a (n = 5). The meaning of ‘*’ is significantly different students t test.
Gremlin-1 Over Expression Causes a
Significant Increase in TGF-β1 Secretion
and Activation
We have demonstrated that Gremlin-1 leads to increased ECM
in skin fibroblasts. We further demonstrated that TGF-β1 does
not regulate Gremin-1 but queried if Gremlin-1 lead to increased
TGF-β1? To test this hypothesis we overexpressed Gremlin-1 in
dermal fibroblasts and quantified secreted TGF-β1 by specific
ELISA. Overexpression of Gremlin-1 led to increased levels of
TGF-β1 secretion compared to vector only transfected cells. In
pcDNA3.1a NHDF mean TGF-β1 secretion was 15.2 pg/mL,
whilst in the supernatant of NHDF transfected with pcDNA3.1a
TGF-β1 secretion was 1,054 pg/mL at 48 h (n = 3, Student’s
t-test, P = 0.0001∗∗∗, values are mean ± SE) (Figure 5A).
Using a luciferase reporter assay we could find activation of a
Smad binding element after transfection of cells with vectors
and transfer of conditioned medium to transfected cells, with
a mean increase in luciferase of over 80% (P ≤ 0.001 Student’s
t-test). This indicates that the TGF-β1 in the medium is active
and productive (Figure 5B).
Because we had found upregulation of TGF-β1 and through
the Smad reporter assay, activation, we sought to measure the
expression of thrombospondin-1 (TSP-1). TSP-1 is a potent
activator of TGF-β1 from its latent non-active form and
thus elevated TSP-1 would indicate a possible mechanism of
activation. After overexpression of Gremlin-1 compared to non-
insert plasmid we found no significant difference in TSP-1 levels
in the media (Figure 5C). This suggests that TGF-β1 increased
through Gremlin-1 is not mediated by TSP-1 increases.
Inhibitors to TGF-β1 Attenuate the
Gremlin-1 Mediated Increase in Collagen
1 Protein
Because we have demonstrated a significant increase in TGF-
β1 after Gremlin-1 over expression we sought to determine if
inhibitors of TGF-β1 pathway would attenuate the Gremlin-
1-mediated increase in collagen expression. We overexpressed
Gremlin-1 using our overexpression construct plus an irrelevant
IgG control antibody or 1 µg of neutralizing TGF-β1 antibody
and measured released collagen. Figure 6A demonstrates a
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FIGURE 3 | Gremlin-1 increased migration in normal healthy dermal fibroblasts. Normal human dermal fibroblasts were transfected with the plasmid construct
pcDNA3.1a with or without the human Gremlin-1 insert. Cells were seeded at high confluency and a scratch assay performed. (A) Representative images.
(B) Images were then quantified in Image J software and wound closure obtained as a percentage of the initial wound. Gremlin-1 increased wound closure in these
cells at 24 h time point (n = 3, Student’s t-test, ∗∗P ≤ 0.0016).
significant increase of collagen release by the Gremlin-1 vector
compared to the pcDNA3.1s vector alone, which was retarded by
incubation with the TGF-β1 neutralizing antibody but not with
the isotype-matched Ig control antibody (P = 0.002 ANOVA;
n = 3). We confirmed neutralizing ability of the antibody by
incubating the antibody with recombinant TGF-β1 protein or
not and using the SMAD reporter luciferase assay, Figure 6B
demonstrates significant reduction of luciferase activity with the
anti-TGF-β1 antibody (Figure 6B, P ≤ 0.001 ANOVA; n = 3).
The TGFβ inhibitor LY2109761 is a dual inhibitor which
inhibits both TGFβRI and TGFβRII (Melisi et al., 2008), thereby
blocking the TGF-β pathway in cells. Use of this inhibitor
attenuated the Gremlin-1-mediated collagen 1 increase in the
NHDF Figure 7C demonstrates that incubation with the TGF-β
receptor inhibitor LY2109761 reduced collagen release compared
to Gremlin-1 overexpression or Gremlin-1 and the vehicle
control (n = 3) (Figure 6C). The downstream mediator appears
to be involved in the signal transduction of Gremlin-1. Although
TGF-β1 signals primarily through the Smad signaling pathway
other what are termed non-canonical pathway can also play a
role. The non-canonical pathway comprises activation of the
TGF-β receptor and instead of Smad activates Ras, Raf and the
ERK signaling. We therefore used inhibitors to MEK U0126 to
block the ERK pathway in fibroblasts plus and minus plasmids
for Gremlin-1. Figure 6D demonstrates that inhibition with
MEK inhibitor U0126 had no effect on Gremlin-1 mediated
increased collagen secretion (P ≥ 0.79 pcDNA3.1ahGrem vs.
pcDNA3.1ahGrem and U0126; P = 0.0137 pcDNA3.1a vs.
pcDNA31.ahGrem).
Gremlin-1 mRNA Is Not Significantly
Different in SSc Fibroblasts
Systemic sclerosis is a highly heterogeneous disease and recent
theories in the field have shifted toward the ideology that
SSc has multiple subtypes, oppose to the classically defined
limited and diffuse cutaneous (Hinchcliff and Mahoney, 2019).
Gremlin-1 was not increased at the mRNA level in early
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FIGURE 4 | siRNA to Gremlin-1 reduces collagen expression. Treatment of NHDF wit Gremlin-1 siRNA: NHDF were co transfected with the plasmid construct
pcDNA3.1a and pcDNA3.1a-hGREM and either a non-targeting (scramble) or Gremlin-1 targeting siRNA. (A) Representative western blot and (B) densitometric
analysis (n = 4, t-test P-value vs. pcDNA3.1a—pcDNA3.1a-hGREM = 0.060653 (SD ± 2.85), pcDNA3.1-hGREM + scramble = 0.044446∗ (SD ± 0.82),
pcDNA3.1a-hGREM + Gremlin-1 siRNA (SD ± 0.63) = 0.723193 and P-value of pcDNA3.1a-hGREM + scramble vs. pcDNA3.1a-hGREM + Gremlin-1
siRNA = 0.0889. (C) Collagen was quantified by Sircol assay after transfection of pcDNA3.1, pCDNA3.1a-hGREM, pcDNA3.1a-hGREM and scramble siRNA or
pcDNA3.1a-hGREM and siRNA Gremlin-1.
FIGURE 5 | Gremlin-1 increases TGF-β1 protein. (A) TGF-β1 was measured by ELISA after overexpression of pcDNA3.1 or pcDNA3.1hGREM, ∗∗∗P ≤ 0.0001;
Student’s t-test; n = 3). (B) Luciferase activity of SBE construct after media was placed onto the cells after transfection with pcDNA3.1 or pcDNA3.1hGREM,
P ≤ 0.001; Student’s t-test; n = 3. (C) TSP-1 levels were measured after plasmid transfection in the conditioned media. No significant difference, P ≥ 0.05; Student’s
t-test; n = 3.
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FIGURE 6 | Gremlin mediates its effects through TGF-β/Smad signaling. (A) Collagen is reduced by TGF-β1 neutralizing antibody. Cells were treated with isotype
matched antibody or TGF-β1 neutralizing antibody and either empty pcDNA3.1a or pcDNA3.1a-hGREM. ∗Significantly different P = ANOVA pcDNA3.1 vs
pcDNA3.1a-hGREM. *P = pcDNA3.1a-hGREM vs. pcDNA3.1a-hGREM and TGF-β1 antibody. (B) TGF-β1 neutralizing antibody reduced SBE luciferase in fibroblasts
P ≤ 0.001 rTGF-β1 vs. rTGF-β1 and neutralizing antibody. (C) Collagen is reduced with LY2109761 with gremlin-1 overexpression. (D) U0126 ERK (10 µM) inhibitor
has no effect of Gremlin-1-induced collagen P≥ 0.05. (E) Gremlin-1 was quantified by qPCR in HC and SSc dermal fibroblasts. Data is individual donors. Dashed
line horizontal is 0 fold change n = 3.
diffuse SSc patient skin samples (patient n = 3). In the SSc
skin patient samples 1 patient showed a twofold increase
in Gremlin-1 mRNA when compared to healthy control,
however the other 2 patients showed a decrease in Gremlin-
1 mRNA (−2 and −1.25-folds) (Figure 6E). It is not possible
to quantify Gremlin-1 at the protein level due to non-
specific antibodies.
Gremlin-1 Small Interfering RNA
Reduced ECM in SSc Dermal Fibroblasts
Using our model system of overexpression of Gremlin-1 we
could find elevated ECM markers associated with fibrosis that
is associated with enhanced TGF-β signaling. We sought to
reduce gremlin expression in 3 SSc early diffuse patients samples.
Employing small interfering RNA (siRNA) we can see a reduction
in collagen release compared to non-targeting control siRNA at
the same concentration 57.8 µg/ml scramble siRNA (SD = 4.5)
vs. 31.5 µg/ml Gremlin-1 siRNA (SD = 6.1), P = 0.0038; Student’s
t-test n = 3 donors (Figure 7A). We could confirm successful
siRNA mediated knockdown of Gremlin-1 by measuring the
mRNA expression after knockdown, compared to scramble
siRNA Gremlin-1 siRNA reduced Gremlin-1 expression by over
60% (Figure 7B), P = 0.0022; Student’s t-test n = 3. In light of
the effect of overexpression of Gremlin-1 inducing collagen via
enhanced TGF-β signaling we sought to examine a downstream
target gene of TGF-β1 CTGF (Black and Trackman, 2008) after
siRNA knockdown of Gremlin-1. CTGF is a known target of
TGF-β1 and mediates fibrosis. Figure 7C demonstrates that
CTGF mRNA is reduced by over 50% in Gremlin-1 siRNA
knockdown cells compared to scramble (P = 0.0002; Student’s
t-test n = 3) and this reduction of CTGF was reduced at the
protein level (Figure 7D). To examine if ablation of Gremlin-
1 reduced cell proliferation we undertook an MTT assay after
siRNA scramble or siRNA to Gremlin-1. No difference was
seen in cell proliferation (Figure 7E). This suggests that cell
proliferation plays no role in the reduction of collagen.
IL-6 but Not IL-13 nor IL-11 Increase
Gremlin-1 in Dermal Fibroblasts
Although TGF-β1 was induced by Gremlin-1, TGF-β1 itself did
not induce Gremlin-1, therefore we sought to determine if IL-
13 induced Gremlin-1 as IL-13 is a known pro-fibrotic molecule
particularly elevated in SSc (O’Reilly, 2013). Incubation of IL-
13 at both 24 and 48 h did not lead to a significant increase in
Gremlin-1 expression in healthy dermal fibroblasts (Figure 8A,
no significant difference, P ≥ 0.05 Two way ANOVA; n = 4).
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FIGURE 7 | Knockdown of Gremlin-1 in SSc mediates reduced ECM in SSc cells. (A) SSc fibroblasts from 3 donors were transfected with scramble or Gremlin-1
siRNA and collagen was quantified by Sircoll assay. Each point is individual donor and the horizontal bar is the mean, P = 0.0038; Student’s t-test; n = 3.
(B) Confirmation of Gremlin-1 knockdown by qRT-PCR after scramble or Gremlin-1 siRNA, P = 0.0022; Student’s t-test; n = 3. (C) CTGF levels after siRNA scramble
control or Gremlin-1 siRNA transfection. Data is normalized to 18S and shown as fold change to scramble siRNA controls, P = 0.0002; Student’s t-test; n = 3.
(D) Western blot of CTGF and α-tubulin to confirm equal protein loading after transfection of scramble or siRNA targeting Gremlin-1 in three different SSc donors.
(E) Absorbance at 570 nm after siRNA Gremlin-1 or scramble control siRNA. No significant difference, P = 0.13; Student’s t-test; n = 3. The meaning of ‘*’ is
significantly different students t test.
To confirm that the recombinant IL-13 we used was
indeed functional we measured colagen1A1 expression by
qPCR (Figure 8B), there was a significant 3.2-fold increase in
COL1A1 gene expression at 24 h (SD = 0.72), P = 0.0009;
Student’s t-test; n = 4 (Figure 8B). This indicates that the
IL-13 is functional and does not modify Gremlin-1. We had
previously described a role for IL-6 trans signaling in Gremlin-
1 and fibrosis (O’Reilly et al., 2014), we confirmed here that
incubation with both IL-6 and soluble IL-6 Receptor leads to
upregulation of Gremlin-1 (Figure 8C), P = 0.0015; Student’s
t-test. IL-6 signals through the IL-6 Receptor but this is not
present on the surface of dermal fibroblasts and needs to
be added in vitro to signal through what is coined trans
signaling (O’Reilly et al., 2014). The main downstream signaling
mechanism from IL-6 signaling is through Janus Kinases (JAKs)
and subsequent phosphorylation of STAT3 leading to gene
expression. To corroborate the role of STAT3 in IL-6 mediated
Gremlin-1 induction we incubated dermal fibroblasts with IL-
6/IL-6R combination and the STAT3 inhibitor S31-201 which
resulted in diminished induction of Gremlin-1 (Figure 8D).
A previous study in vivo also showed induction of STAT3-
mediated Gremlin-1 in lung fibrosis (Wong et al., 2014) and a
recent paper demonstrated that IL-6 trans signaling in idiopathic
pulmonary fibroblasts elevated Gremlin-1, which was reduced
with tocilizumab (Epstein Shochet et al., 2020).
Because IL-11 is an IL-6 family cytokine, that uses
similar downstream signaling pathways as IL-6 and we
have shown that this is both pro-fibrotic in SSc and is
also elevated in the sera of patients (Adami et al., 2021)
we posited that this cytokine would increase Gremlin-1
levels in dermal fibroblasts. Using the dose that we have
found to increase myofibroblast generation (10 ng/ml) we
examined Gremlin-1 expression after 24 h stimulation and
found no significant difference in expression compared
to untreated cultures (untreated 1 vs. 1.15-fold change
P ≥ 0.005; n = 3).
Gremlin-1 Is Elevated in Bleomycin
Model of Fibrosis
Finally, we used the bleomycin model of skin fibrosis, which
is a classic model of skin fibrosis that is dependent on
inflammation and examined using immunohistochemistry
Gremlin-1 expression. Figure 9A shows skin thickness
in NaCl injected control mice and Figure 9B shows
significantly different thickness in bleomycin treated
mice. Figure 9Ci demonstrates few cells expressed
Gremlin-1 in the control NaCl-treated mice whereas the
bleomycin-treated mice the dermal fibroblasts expressed
Gremlin-1 (Figure 9Cii).
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FIGURE 8 | IL-6 but not IL-13 or IL-11 mediates Gremlin-1 upregulation. (A) Gremlin-1 expression in healthy dermal fibroblast after stimulation with recombinant
IL-13 at 24 and 48 h time points. Data is mean and SD and is normalized to 18S expression and shown as fold change to untreated cells. (B) COL1A1 gene
expression is elevated after IL-13 incubation Data is mean and SD and is normalized to 18S Data is the mean and SD. (C) Gremlin-1 gene expression after IL- trans
signaling. Data is the mean and SD and is normalized to 18S and shown as fold change. ∗P = 0.0015; Student’s t-test n = 3. (D) Gremlin-1 gene expression was
quantified by qPCR. Cells were treated with IL-6 and sIL-6 receptor or the STAT3 inhibitor S31-201. Cells were lysed and qPCR performed. Data is the mean and
SD and is normalized to 18S and set as fold change.
DISCUSSION
Gremlin-1 has been previously found to be elevated in SSc
tissues and has been associated with various tissue fibrosis states
including the liver, lung, eye, and kidney (Koli et al., 2006;
Lee et al., 2007; Yang et al., 2012; Wellbrock et al., 2014).
Building upon our previous studies we sought to examine
the role of Gremlin-1 in skin fibrosis further. Rather than
using recombinant protein to elicit the effects we utilized an
overexpression system in primary dermal fibroblasts.
In this study we demonstrated that Gremlin-1 increases
collagen 1 at the protein level in dermal fibroblasts and functional
enhancement of the wound healing/fibrosis response. Alongside
increased collagen 1 protein the study also found an increase
the secretion of TGF-β1 and is in line with data published in
renal cells (Rodrigues-Diez et al., 2012). Given that TGF-β1 is
a major pro-fibrotic cytokine both in liver and lung fibrosis
but also in SSc (Wei et al., 2010; Lafyatis, 2014; Frangogiannis,
2020), we hypothesized that this may lie upstream of Gremlin-
1 regulation and thus predicted that TGF-β1 stimulation would
lead to elevated Gremlin-1.
Interestingly, treatment of the fibroblasts with recombinant
human TGF-β1 did not increase Gremlin-1 expression.
Commercially, available antibodies to Gremlin-1 are notoriously
unreliable and in our hands, we were unable to gain reliable
and reproducible results, hence the measurement of Gremlin-1
at mRNA level and not the protein level. So, we cannot rule
out the possibility that TGF-β1 does regulate Gremlin-1 post
transcriptionally.
Media transfer experiment conducted in this study support
the hypothesis that Gremlin-1 is either acting as a cytokine
itself or increasing secretion of profibrotic cytokine(s) into the
extracellular space. This would further support the hypothesis
that Gremlin-1, perhaps via its downstream affects, is shifting the
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FIGURE 9 | Bleomycin treated mice have elevated skin fibrosis and Gremlin-1 expression. (A) Representative Trichrome staining of NaCl treated mice.
(B) Representative Trichrome staining of bleomycin treated mice- showing excessive skin thickening. Magnification ×10. (C) Immunohistochemistry of Gremlin-1
using specific antibody to Gremlin-1 (i) NaCl treated mice and (ii) bleomycin treated mice. Hematoxylin is the nuclear stain. Magnification ×20.
quiescent cell to a myofibroblast phenotype; a key phenotype in
skin fibrosis (Antic et al., 2013).
We could not find evidence that TGF-β1 upregulates Gremlin-
1 expression at multiple times points but the opposite appears
true in that Gremlin-1 overexpression led to significantly elevated
expression of TGF-β1 into the cell media. This was further
confirmed to be activated as this media could activate the
Smad reporter system, which is a Smad-responsive element
linked to luciferase, further supporting activation of TGF-
β1 by Gremlin-1. Because one of the most potent activators
of TGF-β1 is TSP-1 (Frangogiannis, 2020) in the matched
media we examined if this was elevated. TSP-1 was not
elevated by Gremlin-1 suggesting that activation of TGF-β1
is independent of TSP-1. Other activators of TGF-β1 include
Reactive Oxygen species and the integrin ανβ6 (Munger
et al., 1999). Indeed gremlin-1 has been shown to alter the
expression of β3 integrin to stabilize the VEGF receptor. Thus,
it could be possible, but requires confirmation, that Gremlin-1
activates TGF-β1 leading to increased fibrosis through increased
integrin enhancement.
Because we saw upregulation of TGF-β1 and that we
know TGF-β1 is a potent pro-fibrotic molecule leading to
fibrosis in multiple organs and cells (Frangogiannis, 2020) we
postulated that Gremlin-1-mediated fibrosis is through TGF-β1
signaling causing a fibrotic loop sustaining fibrosis. Thus, we
used neutralizing antibodies to TGF-β1 to neutralize this and
compared to isotype matched antibody we could see impressive
reductions in collagen. We confirmed suppression of TGF-β1
signaling through the luciferase reporter assay and recombinant
TGF-β1. To confirm that this was receptor-mediated we used the
classic TGFβ receptor inhibitor and found that this also reduced
Gremlin-1-mediated collagen expression. Because TGF-β1 can
activated the non-canonical pathway and primarily MAPK we
used the potent MAPK inhibitor and found that this did not
diminish the increase in collagen mediated by Gremlin-1. We
thus confirm that Gremlin-1 mediated fibrosis primarily through
TGF-β1 canonical pathways, however, other non-canonical
pathways could be involved as we cannot exclude the p38
pathway and others. Studies by Sethi et al. (2013) demonstrated
that Gremlin-1 utilized the canonical Smad and MAPK p38
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pathway to induce ECM protein and Lysyl oxidase (LOX) genes
in trabecular meshwork cells. Our work demonstrates that only
the canonical pathway is playing a role in ECM deposition in
these cells and the difference is likely due to different cells types:
meshwork cells of the eye have a more endothelial phenotype.
A limiting factor in this study is the patient number, in
our limited sample Gremlin-1 did not appear increased;
however, SSc is an extremely rare and heterogeneous
disease and securing patient samples is extremely difficult.
However using the patient samples we had we used siRNA
to Gremlin-1 we could significantly reduce Gremlin-
1 and there was a corresponding significant decrease
in collagen and the target gene of TGF-β1 CTGF was
also significantly supressed at both the mRNA and
protein level, suggesting that this is reducing TGF-β
signaling. It is possible also that local concentrations
of Gremlin-1 in SSc are elevated in and around the
skin affected or indeed in the serum. A commercial
ELISA does exist for Gremlin-1 but we are yet to
be convinced of its specificity. Significantly elevated
levels of Gremlin-1 has been demonstrated in renal
fibroblasts and in idiopathic pulmonary fibrosis (Walsh
et al., 2018). It could be that the mRNA expression
is unchanged in the SSc samples but the protein level
is much increased.
We next sought to examine the role of an inducer of
Gremlin-1 in these cells. The primary reason IL-13 was
chosen is that this is a highly fibrotic cytokine which is
significantly elevated in SSc (O’Reilly, 2013). Incubation of
dermal fibroblasts with recombinant IL-13 did not lead to
elevated Gremlin-1. We interpret this that IL-13 does not
directly lead to Gremlin-1 expression. We could confirm it
was functional as collagen mRNA expression increased as
expected. IL-6 trans signaling, which is signaling using the
soluble IL-6 receptor and IL-6 was found by us to induce
collagen (O’Reilly et al., 2014) and we extended this further
by demonstrating that IL-6-mediated-Gremlin-1 is facilitated
through STAT3-as the STAT3 inhibitor S31-201 significantly
retarded this effect. This is in keeping with our previous work
(O’Reilly et al., 2014) and also recent work in lung fibrosis
and most recently bone marrow-derived stromal cells were
found to upregulate Gremlin-1 via IL-6 trans signaling and
this could be retarded with the use of an IL-6 monoclonal
antibody (Clark et al., 2020). Given the importance of IL-
6 in SSc (O’Reilly et al., 2012, 2013), with significantly
elevated levels in the blood and tissues (Hasegawa et al.,
1999), a downstream target of IL-6 such as Gremlin-1 may
be a more realistic target in this disease as the importance
of IL-6 in normal immune functions is critical. Analysis of
the Gremlin-1 promoter sequence demonstrates that it has
STAT binding sequenced contained within. The relevance
of inflammatory regulation of Gremlin-1 is demonstrated
in our recent study in which RNA sequencing of skin
fibroblasts from mice with a deletion in the nfkb subunit
c-Rel revealed significantly reduced levels of Gremlin-1 in KO
compared to wildtype mice (Worrell et al., 2020). Because
IL-11 is an IL-6 family cytokine and we have recently
described its pro-fibrotic role in SSc (Adami et al., 2021),
we hypothesized that this would lead to increased Gremlin-
1 expression similar to IL-6 stimulation. Surprisingly, we
found no increased expression of Gremlin-1 after stimulation,
suggesting some specificity to its response. This could be
attributed to the fact that IL-11 stimulation in stromal cells
preferentially chooses ERK signaling over STAT3 signaling
(Adami et al., 2021).
Finally, we utilized the bleomycin animal model
of fibrosis and determined Gremlin-1 expression
in situ and found, compared to the control NaCl
mice, that Gremlin-1 expression in fibroblasts was
elevated. This further underscores the importance of
Gremlin-1 in dermal fibrosis and speculate that this is
inflammation-driven.
Overall, this study is demonstrating a role for
Gremlin-1 in the accumulation of ECM molecules in
SSc, which could be used a novel target to not only
investigate treatments into the disease but further assess
its etiology. Small molecule inhibitors to Gremlin-
1 are not available yet but the target would be a
valid one as post-natally expression of Gremlin-1 is
negligible. Furthermore, activation of Gremlin-1 maybe
a common pathway of all fibrotic diseases, which is a
component of 45% of all deaths in the western world
(Wynn, 2008).
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